A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Trial Profile

A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Liver metastases; Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Acronyms ILUMINET
  • Most Recent Events

    • 06 Mar 2017 Planned End Date changed from 1 Oct 2018 to 1 Jan 2021.
    • 06 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2021.
    • 28 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top